IMR Press / EJGO / Volume 34 / Issue 1 / pii/1630905359561-2069442524

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Characteristics and prognosis of ovarian metastatic tumors: review of a single-institution experience
Show Less
1 Department of Obstetrics and Gynecology, Oncology Unit, Bakirkoy Woman and Children Training and Research Hospital, Istanbul
2 Department of Obstetrics and Gynecology, Bakirkoy Woman and Children Training and Research Hospital, Istanbul (Turkey)
Eur. J. Gynaecol. Oncol. 2013, 34(1), 75–78;
Published: 10 February 2013
Abstract

Background: To evaluate the clinico-pathological characteristics and role of surgery in patients with ovarian metastasis. Materials and Methods: Clinical data from 51 patients with pathologically confirmed ovarian metastasis were reviewed. Results: Ovarian metastasis accounted for 14% of all malignant ovarian neoplasms (51/364). Of the 51 metastatic ovarian tumor cases, 24 originated from gynecologic malignancies, while 27 originated from non gynecologic malignancies. Optimal cytoreduction was performed in 88% and 37% of patients with metastases of gynecologic and non-gynecologic origin, respectively. Patients with ovarian metastasis had a two-year survival rate in 82% of the gynecologic group and 70% of the non-gynecologic group (p = 0.35). The five-year survival rate of patients with non-gynecologic tumor origin (29%) was significantly worse (p = 0.04) than the survival rates of those with tumors of gynecologic origin (61%). In the non-gynecologic group, the five-year survival rates were significantly different between patients who were performed optimal cytoreductive surgery vs those without this procedure (42% and 20%, respectively; p = 0.04). Conclusion: Although complete surgical resection is not achievable in approximately two-thirds of patients with metastases of non-gynecological origin, optimal tumor cytoreduction appears to improve survival, which is statistically significant in all patients with ovarian metastatic tumors.
Keywords
Ovarian metastasis
Cytoreductive surgery
Krukenberg tumor
Share
Back to top